scholarly journals Prevalence of Steatosis Hepatis in the Eurotransplant Region: Impact on Graft Acceptance Rates

HPB Surgery ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Simon Moosburner ◽  
Joseph M. G. V. Gassner ◽  
Maximilian Nösser ◽  
Julian Pohl ◽  
David Wyrwal ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Allograft ◽  
Donor Pool ◽  
Steatotic Liver ◽  
Steatosis Hepatis ◽  
Acceptance Rates ◽  
Macrovesicular Steatosis ◽  
Future Concepts

Due to the shortage of liver allografts and the rising prevalence of fatty liver disease in the general population, steatotic liver grafts are considered for transplantation. This condition is an important risk factor for the outcome after transplantation. We here analyze the characteristics of the donor pool offered to the Charité – Universitätsmedizin Berlin from 2010 to 2016 with respect to liver allograft nonacceptance and steatosis hepatis. Of the 2653 organs offered to our center, 19.9% (n=527) were accepted for transplantation, 58.8% (n=1561) were allocated to other centers, and 21.3% (n = 565) were eventually discarded from transplantation. In parallel to an increase of the incidence of steatosis hepatis in the donor pool from 20% in 2010 to 30% in 2016, the acceptance rates for steatotic organs increased in our center from 22.3% to 51.5% in 2016 (p < 0.001), with the majority (86.9%; p > 0.001) having less than 30% macrovesicular steatosis hepatis. However, by 2016, the number of canceled transplantations due to higher grades of steatosis hepatis had significantly increased from 14.7% (n = 15) to 63.6% (42; p < 0.001). The rising prevalence of steatosis hepatis in the donor pool has led to higher acceptance rates of steatotic allografts. Nonetheless, steatosis hepatis remains a predominant phenomenon in discarded organs necessitating future concepts such as organ reconditioning to increase graft utilization.

scholarly journals Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease

Biology ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 122
Author(s):  
Jun-Hyuk Lee ◽  
Hye-Sun Lee ◽  
Byoung-Kwon Lee ◽  
Yu-Jin Kwon ◽  
Ji-Won Lee
Keyword(s):  
Skeletal Muscle ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Muscle Mass ◽  
Fatty Liver Disease ◽  
Skeletal Muscle Mass ◽  
Liver Fat ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Although sarcopenia is known to be a risk factor for non-alcoholic fatty liver disease (NAFLD), whether NAFLD is a risk factor for the development of sarcopenia is not clear. We investigated relationships between NAFLD and low skeletal muscle mass index (LSMI) using three different datasets. Participants were classified into LSMI and normal groups. LSMI was defined as a body mass index (BMI)-adjusted appendicular skeletal muscle mass <0.789 in men and <0.512 in women or as the sex-specific lowest quintile of BMI-adjusted total skeletal muscle mass. NAFLD was determined according to NAFLD liver fat score or abdominal ultrasonography. The NAFLD groups showed a higher hazard ratios (HRs) with 95% confidence intervals (CIs) for LSMI than the normal groups (HRs = 1.21, 95% CIs = 1.05–1.40). The LSMI groups also showed a higher HRs with 95% CIs for NAFLD than normal groups (HRs = 1.56, 95% CIs = 1.38–1.78). Participants with NAFLD had consistently less skeletal muscle mass over 12 years of follow-up. In conclusion, LSMI and NAFLD showed a relationship. Maintaining muscle mass should be emphasized in the management of NAFLD.

scholarly journals Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 270
Author(s):  
Luca Rinaldi ◽  
Pia Clara Pafundi ◽  
Raffaele Galiero ◽  
Alfredo Caturano ◽  
Maria Vittoria Morone ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Smoking Habit ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical and physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it as a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, and other elements of MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, and weight loss) determine an improvement in IR, MS, and both clinical and histologic liver picture. NAFLD and IR are bidirectionally correlated and, consequently, the development of pre-diabetes and diabetes is the most direct consequence at the extrahepatic level. In turn, type 2 diabetes is a well-known risk factor for multiorgan damage, including an involvement of cardiovascular system, kidney and peripheral nervous system. The increased MS incidence worldwide, above all due to changes in diet and lifestyle, is associated with an equally significant increase in NAFLD, with a subsequent rise in both morbidity and mortality due to both metabolic, hepatic and cardiovascular diseases. Therefore, the slowdown in the increase of the “bad company” constituted by MS and NAFLD, with all the consequent direct and indirect costs, represents one of the main challenges for the National Health Systems.

scholarly journals Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0182708 ◽  
Author(s):  
Jae Yeon Lee ◽  
Dong Wook Shin ◽  
Jeong Won Oh ◽  
Won Kim ◽  
Sae Kyung Joo ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Sexual Dysfunction ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Female Sexual Dysfunction ◽  
Premenopausal Women ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Relationship of Non Alcoholic Fatty Liver Disease (NAFLD) and Serum Level of Thyroid Stimulating Hormone (TSH) in Normal Reference Range

2021 ◽  
pp. 33-39
Author(s):  
Doaa Ameen Khalil ◽  
Yasser Mohammed Abdul Raouf ◽  
Amal Said Al-Bendary ◽  
Kamal Mohamed Okasha
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Serum Level ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Risk Factor ◽  
Serum Levels ◽  
Thyroid Stimulating Hormone ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) can increase the incidence of cardiovascular disease and hepatocellular carcinoma. Thyroid hormones also play important roles in hepatic lipid metabolism and hepatic insulin resistance. Hypothyroidism is associated with reduced lipolysis and decreased liver uptake of free fatty acids derived from triglycerides. In recent years, the correlation between overt or subclinical hypothyroidism and NAFLD has been discussed. The relationship between NAFLD and thyroid function parameters remains unclear. Aim: We aimed to evaluate the relationship between serum level of Thyroid Stimulating Hormone (TSH) within normal reference range and Non Alcoholic fatty liver Disease (NAFLD). Subjects and Methods: This is a cross sectional case control study on 40 patients with NAFLD and a control group of 20 healthy individuals, who were attendants of Outpatient Clinic of Internal Medicine Department of Tanta University Hospitals and EL-Menshawy General Hospital from February 2018 to the end of January 2019. Results: In the present study, univariate regression analysis showed that serum levels of AST, FT3, FT4 and Anti-TPO were independent risk factors of NAFLD, while in multivariate analysis the only independent risk factor of NAFLD was Anti-TPO serum level. Conclusion: Serum levels of AST, FT3, FT4 and Anti-TPO were independent risk factors of NAFLD in univariate regression analysis, while in multivariate analysis the only independent risk factor of NAFLD was Anti-TPO serum level. Despite the positive correlation between serum TSH level and grade of NAFLD, the study didn’t show serum TSH level as independent risk factor of NAFLD.

Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease

2010 ◽  
Vol 31 (3) ◽  
pp. 348-353 ◽  
Author(s):  
Paulo Adriano Schwingel ◽  
Helma P. Cotrim ◽  
Bernardo Rios Salles ◽  
Carlos Eduardo Almeida ◽  
Crimério Ribeiro dos Santos ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Anabolic Androgenic Steroids ◽  
Androgenic Steroids
Sign in / Sign up

Export Citation Format

Share Document